MOUNTAIN VIEW, Calif .– (BUSINESS WIRE) – August 4, 2021–
NeuroPace, Inc. (NASDAQ: NPCE), a medical technology company dedicated to transforming the lives of people with epilepsy, today announced the general launch of its nSight platform, an online portal that helps physicians deliver care more personalized and data-driven epilepsy by allowing them to remotely review patient progress, discover actionable insights and track overall patient outcomes from their clinic.
This press release features multimedia. See the full version here: https://www.businesswire.com/news/home/20210804005401/en/
The RNSÂ® System is the only FDA-approved epilepsy device that continuously monitors brain activity, provides personalized treatment by responding in real time to a patient’s unique epileptic activity, and records intracranial EEG data that can help physicians optimize patient outcomes.
âThe RNS System provides drug-resistant epilepsy patients with unprecedented seizure reduction, while providing physicians with unprecedented visibility into the ongoing brain activity of their patients,â said Mike Favet, CEO of NeuroPace. âWe believe that the brain data captured by the RNS system is a major technological differentiator: it gives physicians additional information, so they can make more informed treatment decisions for their patients. With the launch of the nSight platform, RNS system data is more streamlined, more accessible and more actionable than ever. “
As part of the nSight Platform offer, NeuroPace has partnered with Monitoring of seizures, one of the most widely used electronic seizure diary applications, to help patients and clinicians more reliably monitor and manage seizures. The Seizure Tracker mobile app gives patients and caregivers the ability to record videos of seizures as they occur, and to record seizure events and details afterward. It also integrates with Amazon Alexa so patients can verbally record the onset and end of a seizure.
Through the partnership of the companies, patients can choose to share Seizure Tracker information with their physicians through the nSight platform. This allows physicians to better assess their patients’ seizure burden, identify potential seizure triggers, and see trends in seizure activity based on medication or lifestyle changes.
âWe are delighted with what this partnership brings. When patients monitor their seizures, it allows them to take an active role in managing their epilepsy. And when this information is combined with data from the RNS system, physicians can discover powerful information to inform patient care, âsaid Robert Moss, CEO of Seizure Tracker.
âI’m working as a team with my doctor to review the data from my RNS system and compare it to the seizure diary to identify triggers,â said Heather, a patient who has had the RNS system since 2015. âWe found that the juice was juice. orange was a major trigger for me, I started taking my medication with water and immediately eliminated this post-medication seizure activity.
The nSight platform is particularly useful with the growing demand for telehealth visits. For patients with epilepsy, Seizure Tracker can provide a convenient way to track daily seizure activity and share this information with their doctor. For physicians, the nSight platform can provide a more complete picture of their patient’s epilepsy, all in one centralized location.
About the RNSÂ® System
The RNS Â® System, a paradigm shift treatment for focal drug-resistant epilepsy, is the only brain-responsive neuromodulation system approved by the FDA. Closed-loop technology delivers personalized, data-driven, seizure-source-focused treatment by continuously monitoring brain activity, recognizing a patient’s unique seizure pattern, and responding in real time with imperceptible stimulation to prevent seizures. By recording current EEG data, the RNS system provides physicians with a ‘single window to the brain’, allowing them to remotely monitor their patients, obtain information based on brain activity, and use that information to optimize patient care.
Long-term clinical studies show that the RNS system allows a significant reduction in seizure frequency and lasting improvements in quality of life and cognition, without side effects related to stimulation. 1
The RNS system is available at most comprehensive epilepsy centers in the United States and is widely covered by insurance. It is currently approved in the United States for patients 18 years of age and older with drug-resistant focal epilepsy. View important safety information on www.neuropace.com/safety/.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace was founded to transform the lives of people with epilepsy, a debilitating neurological disorder affecting approximately 1 in 26 people. 2 In 2013, it introduced the RNSÂ® system, the first and The only FDA-approved, closed-loop, responsive brain neuromodulation system that delivers truly personalized, data-driven treatment. In addition to treating drug-resistant focal epilepsy, the long-term EEG data recorded by the RNS system helps advance scientific understanding of the human brain. The company’s brain-responsive neuromodulation technology has the promise of potentially treating other neurological disorders that impact the quality of life of millions of people around the world. For more information, please visit www.neuropace.com.
About Seizure Tracker â¢
Founded in 2007 by parents of a child with daily seizures, Seizure Tracker â¢ provides a collection of web, mobile and voice interaction tools for people living with seizures to collect epilepsy-related information and easily share that data with their physicians. Reports generated on the Seizure Tracker system provide comprehensive data visualizations comparing therapies to changes in seizure activity while highlighting trends. With a close connection to the epilepsy patient, physician and research communities, Seizure Tracker has grown to become the largest collection of data on seizures and associated therapies in the world, opening new doors for data-driven research. and effectively changing the way we think about crisis management. For more information on the Seizure Tracker system, visit SeizureTracker.com or by e-mail to [email protected]
1 Nair, et al, Neurology, 2020
2 Foundation of epilepsy. “Facts on Seizures and Epilepsy.”
View source version on businesswire.com:https://www.businesswire.com/news/home/20210804005401/en/
CONTACT: Shay Smith
Health + Commerce
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: DATA MANAGEMENT HEALTH TECHNOLOGY MOBILE / WIRELESS SOFTWARE GENERAL HEALTH
Copyright Business Wire 2021.
PUB: 08/04/21 08: 00 / DISC: 08/04/21 08:01